Ablacon, a Wheat Ridge, Colorado-based provider of AI-guided atrial fibrillation therapies, today announced that it has raised $21.5 million in a series A round led by Ajax Health that it says will be used to advance its technology pipeline and finance clinical trials.
It also revealed that Duke Rohlen, a veteran of Epix Therapeutics, Spirox, CV Ingenuity, and FoxHollow Technologies, has been appointed chair and CEO.
“Atrial Fibrillation (AF) is the most common heart arrhythmia in the world.
Around 30 million people are predicted to be affected by 2060 in the U.S. and in Europe,” CTO Dr. Philip Haeusser said.
“Ablacon builds a real-time high-precision diagnosis system for atrial fibrillation.”
Ablacon’s technology, which it calls Electrographic Flow, uses AI and machine learning to analyze and visualize the flow of action potentials within the heart to “quantitatively” and “qualitatively” detect signs of atrial fibrillation, which is caused by poor blood flow and can increase the risk of cardiovascular conditions, such as stroke and heart attack.